Q&A: Prestige-ous plan

Tim Connors, Prestige Brands

Tim Connors, Prestige Brands

Prestige Brands earlier this year completed its acquisition of 17 GlaxoSmithKline brands. Drug Store News sat with Prestige SVP sales and marketing Tim Connors to discuss what’s next.

DSN: What is the next step? 

Tim Connors: Our strategic value creation plan consists of three components: 

  1. Grow our brands organically; 

  2. Acquire [additional] OTC brands; and 

  3. Strategically manage our portfolio. 

That’s our roadmap to becoming a $1 billion OTC company.

DSN: What are some of the synergies that you see coming out of Prestige’s broader portfolio. 

Connors: The real benefit from having an expanded brand portfolio, simply put, [is] the shared knowledge across our brand portfolios in analgesics, gastrointestinal, cough-cold, ear-eye, oral care, sleep aids, dermatology and household. Developing and sharing consumer insights, new product development technologies, class of trade expertise and a deeper knowledge of the consumer are the most important building blocks for our brands long term. 

DSN: Can you provide an example?

Connors: Dramamine. ... We [uncovered] a consumer insight that moms use the [adult] product for their kids. ... So we came out with a new Dramamine for Kids with a lower dose that would be applicable for children under 13 [years of age]. 

Login or Register to post a comment.